Simulating sequential multiple assignment randomized trials to generate optimal personalized warfarin dosing strategies

Clinical Trials

Volumn 11, Issue 4, 2014, Pages 435-444

  Rich, Benjamin ^a   Moodie, Erica E M ^b   Stephens, David A ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

BLOOD CLOTTING TIME; CASE STUDY; CONFERENCE PAPER; DOSE RESPONSE; DRUG COST; DRUG MECHANISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MATHEMATICAL PHENOMENA; OPTIMAL DRUG DOSE; PRIORITY JOURNAL;

EID: 84901827385     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774513517063     Document Type: Conference Paper

References (24)

1. Hirsh J, Dalen JE, Anderson DR. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001 ; 119: 8S - 21S
2. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007 ; 167 (13). 1414-19
3. Moodie EEM, Stephens DA. Estimation of dose-response functions for longitudinal data using the generalized propensity score. Stat Methods Med Res. 2012 ; 21: 148-67
4. Eriksson N, Wadelius M. Prediction of warfarin dose: Why, when and how?. Pharmacogenomics. 2012 ; 13 (4). 429-40
5. Steward D, Haining R, Henne K. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997 ; 7 (5). 361-67
6. Rost S, Fregin A, Ivaskevicius V. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004 ; 427 (6974). 537-41
7. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 ; 360 (8). 753-64
8. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013 ;:
9. Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists?. N Engl J Med. 2013 ;:
10. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007 ; 116 (22). 2563-70
11. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013 ;:
12. Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013 ;:
13. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010 ; 87 (5). 572-78
14. Fusaro VA, Patil P, Chi C-L, Contant CF, Tonellato PJ. A systems approach to designing effective clinical trials using simulations. Circulation. 2013 ; 127: 517-26
15. Schwarz UI, Ritchie MD, Bradford Y. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008 ; 358 (10). 999-1008
16. Wilson SE, Costantini L, Crowther MA. Paper-based dosing algorithms for maintenance of warfarin anticoagulation. J Thromb Thrombolysis. 2007 ; 23: 195-98
17. Cafolla A, Melizzi R, Baldacci E, et al. 'Zeus' a new oral anticoagulant therapy dosing algorithm: A cohort study. Thromb Res. 2011 ; 128 (4). 325-30
18. Nielsen PB, Lundbye-Christensen S, Larsen TB, Kristensen SR, Hejlesen OK. Monitoring of anticoagulant therapy applying a dynamic statistical model. Comput Methods Programs Biomed. 2013 ; 110: 380-88
19. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993 ; 21 (4). 457-78
20. Rich B, Moodie EEM, Stephens DA. Adaptive individualized dosing in pharmacological studies: Generating candidate dynamic dosing strategies for warfarin treatment, submitted.. :
21. Blesius A, Chabaud S, Cucherat M, et al. Compliance-guided therapy: A new insight into the potential role of clinical pharmacologists. Clin Pharmacokinet. 2006 ; 45 (1). 95-104
22. Chakraborty B. Dynamic treatment regimes for managing chronic health conditions: A statistical perspective. Am J Pub Health. 2011 ; 101 (1). 40-45
23. Chakraborty B, Moodie EEM Statistical Methods for Dynamic Treatment Regimes: Reinforcement Learning, Causal Inference, and Personalized Medicine. New York: Springer ; 2013 :
24. Rich B, Moodie EEM, Stephens DA, Platt RW. Model checking with residuals for g-estimation of optimal dynamic treatment regimes. Int J Biostat. 2010 ; 6 (2). 12